Nanobiotix SA NBTX announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.1100 evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors (pembrolizumab or nivolumab) for advanced cancer patients.All 21 patients with primary cutaneous melanoma had shown prior resistance to anti-PD-1, and treatment with RT-activated JNJ-1900 (NBTXR3), followed by anti-PD-1, showed a favorable safety profile:Nanobiotix confirmed injection feasibility at the r ...